CLICK HERE to go to the SDOH in Cancer Podcast Page!
Social determinants of health (SDOH), such as locale, race, age, education, literacy, and income can have a significant impact on the prevention of cancer and a patient’s experience and outcomes during treatment. SDOH has been shown to influence cancer screening rates, mortality rates, differences in diagnosis and treatment for various populations and can lead to psychological distress in both the patients and caregivers. This program will provide the knowledge and skills for health care professionals to recognize SDOH barriers to prevention and treatment of cancer which will increase the quality of care provided to cancer patients.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians, psychologists, social workers, dietitians, and other health care professionals who are interested in learning about the impact of social determinants of health in cancer care.
After completing this activity, the participant should be better able to:
Release Date: March 11, 2024
Expiration Date: March 11, 2025
Estimated time to complete the activity: 2 hours
|
Reginald Tucker-Seeley, ScD, ScM, MA - (Course Director) Principal/Owner, Consultant Health Equity Strategies and Solutions Los Angeles, California |
 |
Narjust Florez, MD Associate Director, The Cancer Care Equity Program Thoracic Oncologist, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Member of the Faculty Harvard Medical School Boston, Massachusetts |
 |
Erica T. Warner, ScD, MPH Assistant Professor of Medicine Massachusetts General Hospital Harvard Medical School Boston, Massachusetts |
 |
Karen M. Winkfield, MD, PhD Professor of Radiation Oncology Vanderbilt University Medical Center; Ingram Professor of Cancer Research Vanderbilt Ingram Cancer Center; Professor of Medicine Meharry Medical College; Executive Director Meharry-Vanderbilt Alliance Nashville, Tennessee |
 |
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and ViralEd, Inc. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
PACE designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours.
PACE designates this continuing medical education activity for 2.0 contact hour(s)(0.2 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008073-9999-24-067-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test and the activity evalutation form, transcript information will be sent to the NABP CPE Monitor Serv ice within 4-6 weeks.
 |
PACE has been authorisezed byt the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until March 8, 2025. PAs shoudl only claim credit commensurate with the extent of their particpation. |
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling or distributing healthcare products by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no financial relationships.
Reginald Tucker-Seeley, ScD, ScM, MA, faculty for this educational activity, has no relevant financial relationships.
Narjust Florez, MD, faculty for this educational activity, has the following relevant financial relationships:
Erica T. Warner, ScD, MPH, faculty for this educational activity, has the following relevant financial relationships:
Karen M. Winkfield, MD, PhD, faculty for this educational activity, has the following relevant financial relationships:
1. There are no fees for participating in and receiving CME credit for this activity.
2. During the period March 11, 2024, through March 11, 2025, participants must read the educational objectives and faculty disclosures and study the educational activity.
3. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation, using the link below.
4. Upon registering and successfully completing the post-test with 4 out of 5 correct or better and activity evaluation, your certificate will be made available immediately.
To Claim Credit for this program, please go to: https://paceducation.com/SDOHinCancer
For additional information about the accreditation of this activity, please visit: https://partnersed.com
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This program requires HTML 5 enabled web browsers such as; Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
An Independent CME Activity Jointly Provided by Partners for Advancing Clinical Education and ViralEd, Inc.
This activity is supported by independent educational grants from Merck & Co. Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc. and Seagen Inc.
